AUTHORS
Robert Stuver, MD, Kwang Wooahn, PhD2, Yikun Shi, MS3, Tiening Chen, MS4, Jinalben Patel, MPH, BDS5, Cameron J. Turtle6, Peter Riedell7, Alex Francisco Herrera, MD8, Mazyar Shadman, MD, MPH9, Mehdi Hamadani, MD10, Craig Sauter, MD11, R. Alejandro Sica, MD12
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 University of Chicago, Chicago, Illinois, United States
8 City of Hope National Medical Center, Duarty, California, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Memorial Sloan Kettering Cancer Center, New York, United States
12 Montefiore Einstein, Bronx, New York, United States
ABSTRACT
Background: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive HTLV-1-associated T-cell lymphoma with poor survival. Although allogeneic hematopoietic cell transplantation (allo-HCT) is considered the only potentially curative therapy, most published transplant data originate from Japan, while outcomes in North American patients, especially for those of Afro-Caribbean descent, remain poorly characterized. The role of autologous HCT (auto-HCT) is even less well defined. We analyzed contemporary CIBMTR registry data to evaluate outcomes following allo-HCT and auto-HCT in ATLL.
Methods: Adult patients undergoing first allo-HCT or first auto-HCT for ATLL between 2008 and 2024 were identified from the CIBMTR registry. Patients receiving umbilical cord blood grafts and those without research consent were excluded. Primary endpoints included overall survival (OS), progression-free survival (PFS), cumulative relapse incidence (RI), graft-versus-host-disease (GVHD) rates, and non-relapse mortality (NRM).
Results: A total of 264 patients from 108 centers met eligibility criteria, including 213 undergoing first allo-HCT and 51 undergoing first auto-HCT. Median age was 50.7 years (range: 18-80). The cohort reflected the epidemiology of ATLL in North America, with 52% of patients identifying as Black or African American. For allo-HCT, most patients had lymphoma (39%, N=82) or acute (32%, N=67) subtype, followed by chronic (3%, N=7) and smoldering (1%, N=3), whereas for auto-HCT, most patients had lymphoma subtype (55%, N=28). Among allo-HCT recipients, 60% underwent transplant in complete remission (CR) compared with 75% of auto-HCT recipients. Post-transplant cyclophosphamide as GVHD prophylaxis was used in 50% of patients.
With a median follow-up of 35.7 months among survivors, three-year PFS and OS following allo-HCT was 37% (95% CI, 30-45) and 48% (95% CI, 40-55). Three-year PFS and OS following auto-HCT was 44% (95% CI, 29-60) and 49% (95% CI, 33-65), respectively. Relapse was the predominant cause of treatment failure, with 3-year cumulative RI of 47% after allo-HCT and 52% after auto-HCT. NRM was higher following allo-HCT (16% at 3 years) compared with auto-HCT (5%). Among allo-HCT recipients, the 6-month grade 2-4 acute GVHD rate was 24% and the 3-year moderate/severe chronic GVHD rate was 22%. Three-year GVHD-free, relapse-free survival following allo-HCT was 25%.
We next analyzed outcomes by subtype and disease status among allo-HCT recipients. Three-year PFS for acute, lymphoma, chronic and smoldering subtypes was 28%, 44%, 67%, and non-evaluable (NE, only 3 patients) (P=0.24). Three-year OS in similar order was 40%, 53%, 86%, and NE (P=0.54). Among all subtypes, allo-HCT in CR was associated with significantly improved PFS (3-year PFS in CR: 42% versus PR: 29%; P=0.02) and OS (3-year OS in CR: 53% versus PR: 42% P=0.04). On multivariable analysis among allo-HCT recipients adjusting for age, sex, race, subtype, performance status, conditioning intensity, time to transplant, total number of lines of therapy, disease status at transplant, GVHD prophylaxis, and year of transplant, disease status at transplant was the only variable independently associated with improved PFS (P=0.04; HR for PR: 1.4, 95% CI 0.9-2.2; HR for chemoresistant: 2.0, 95% CI 1.1-3.4) and OS (P=0.03; HR for PR: 1.5, 95% CI 1.0-2.3; HR for chemoresistant: 1.8, 95% CI 1.1-3.1).
Conclusions: This study represents one of the largest contemporary analyses of hematopoietic cell transplantation for ATLL outside of Japan, reinforcing allo-HCT as a curative treatment, especially for aggressive subtypes, producing approximately 50% 3-year OS in a disease associated with poor prognosis. However, relapse continues to be the principal cause of treatment failure. Disease status at transplant, rather than subtype, was the dominant determinant of outcome, highlighting the need for improved pre-transplant disease control and post-transplant maintenance strategies. Although interpretation is limited by selection bias and the relatively small number of auto-HCT recipients, the favorable outcomes observed following auto-HCT suggest that consolidation with auto-HCT may represent a reasonable therapeutic option for carefully selected patients, though these findings should be confirmed prospectively. Future studies should define the optimal integration of transplantation with emerging targeted therapies, antiviral strategies, and cellular immunotherapies.
DISCLOSURES
Robert Stuver, MD: PleXus Communications - Honoraria; Pfizer - Research Funding; Step Pharma - Research Funding